0
Abstract: Poster Presentations |

NEUTROPHIL ELASTASE INHIBITOR REDUCES THE LEVELS OF HMGB-1 - WHICH IS ONE OF THE KEY MEDIATORS IN THE DEVELOPMENT OF ALI/ARDS FREE TO VIEW

Yuki Okamatsu, PhD*; Koichi Kimura, PhD; Satoshi Takehiro, MD; Yukiko Ogata, MD; Toyojiro Matsuishi, PhD
Author and Funding Information

Department of Pediatrics & Child Health, Kurume University School of Medicine, Kurume City, Japan


Chest


Chest. 2009;136(4_MeetingAbstracts):36S. doi:10.1378/chest.136.4_MeetingAbstracts.36S
Text Size: A A A
Published online

Abstract

PURPOSE:  While many studies have shown that a neutrophil elastase inhibitor (Sivelestat) prevents the progression of acute lung injury (ALI) or acute respiratory distress syndrome (ARDS), the effect of Sivelestat in children with ALI/ARDS has been difficult to assess. Recently HMGB-1 has been proposed as one of the late mediators of sepsis or lipopolysaccharide endotoxin lethality, although it is unknown well what kind of role HMGB-1 plays in diseases. The aim of our study is to evaluate the effect of Sivelestat and to determine whether it can reduce the levels of HMGB-1 in children with ALI/ARDS.

METHODS:  Eight children with a diagnosis of ALI or ARDS in our pediatric intensive care unit had been parted randomly into two groups. Neutrophil elastase activity (NEA) and HMGB-1 were measured as inflammatory markers. PaO2/FiO2 (P/F) ratio, A-aDO2 and Lung Injury Score (LIS) were also measured as respiratory markers.

RESULTS:  Among the 8 children enrolled in this study (total mean age was 6.5 ± 4.5 years,there is no significant difference between two groups), all cause of ALI/ARDS were direct lung injuries, 7 pneumonia cases and one being drowned with the pond.The group treated with Sivelestat had significantly short periods of hospitalization and respirator management in comparison with the control group. NEA as an acute inflammatory promoter was lower in the treated group at day1 which becomes peak. HMGB-1 increases in a time internal from several hours to days after the beginning of inflammation. Treated group had significantly lower value of HMGB-1 at day7.

CONCLUSION:  Svelestat has clinically effective in children with ALI/ARDS. Increase of NEA seems to be suppressed in the treated group after the ALI/ARDS emerging. However, the detailed mechanism of our result that the group treated with Sivelestat had significantly lower value of HMGB-1 at day7 is remain unclear, we suggest that Sivelestat has a depressive effect at inflammation of subacute period.

CLINICAL IMPLICATIONS:  There is clinical effect of Neutrophil elastase inhibitor which reduce HMGB-1 at subacute piriod in children with ALI/ARDS.

DISCLOSURE:  Yuki Okamatsu, No Financial Disclosure Information; No Product/Research Disclosure Information

Tuesday, November 3, 2009

12:45 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543